Benzoxazolone Carboxamides: Potent and Systemically Active Inhibitors of Intracellular Acid Ceramidase**

Daniela Pizzirani, Anders Bach, Natalia Realini, Andrea Armirotti, Luisa Mengatto, Inga Bauer, Stefania Girotto, Chiara Pagliuca, Marco De Vivo, Maria Summa, Alison Ribeiro, and Daniele Piomelli*

Abstract: The ceramides are a family of bioactive lipid-derived messengers involved in the control of cellular senescence, inflammation, and apoptosis. Acid ceramidase hydrolysis by acid ceramidase (AC) stops the biological activity of these substances and influences survival and function of normal and neoplastic cells. Because of its central role in the ceramide metabolism, AC may offer a novel molecular target in disorders with dysfunctional ceramide-mediated signaling. Here, a class of benzoxazolone carboxamides is identified as the first potent and systemically active inhibitors of AC. Prototype members of this class inhibit AC with low nanomolar potency by covalent binding to the catalytic cysteine. Their metabolic stability and high in vivo efficacy suggest that these compounds may be used as probes to investigate the roles of ceramide in health and disease, and that this scaffold may represent a promising starting point for the development of novel therapeutic agents.

The sphingolipids are a class of bioactive lipid molecules that serve multiple regulatory functions.[1] They contribute to key cellular processes[2] and are involved in the pathogenesis of inflammation and neuropathic pain.[3] The ceramides, a highly heterogeneous family of N-acylated sphingosines with long-chain fatty acids, hold a central position in sphingolipid metabolism[4] and have attracted considerable attention because of their proposed participation in cellular senescence,[5] inflammation,[6] and apoptosis.[7] Additionally, the ceramides are metabolic precursors of sphingosine-1-phosphate (SIP), a lipid mediator that enhances cell survival and proliferation by activating selective G protein-coupled receptors.[8] The pharmacology of sphingolipid signaling is still nascent, yet small-molecule modulators of ceramide production and degradation might open new avenues of therapeutic intervention in pathological conditions, including cancer, inflammation, and pain.[9]

AC is a lysosomal cysteine amidase that catalyzes the hydrolysis of ceramide into sphingosine and fatty acid (Figure 1). As this reaction is a crucial step in ceramide degradation and SIP biosynthesis,[10] AC inhibition can impact the balance between cell proliferation and death, influencing both growth and survival of normal and neoplastic cells. Although several AC inhibitors have been reported, the majority of these compounds are structural analogues of ceramide and are limited in their use by low inhibitory potency and/or lack of systemic activity (Figure 2, and Table S1 in the Supporting Information).[11,12] We previously identified the antineoplastic drug carmofur (5-fluoro-N-hexyl-2,4-dioxo-pyrimidine-1-carboxamide, 8; Figure 3) as the first nanomolar inhibitor of AC (median inhibitory concentration, IC₅₀, for rat AC = 29 nM).[13] This result prompted us to expand the class of 2,4-dioxopyrimidine-1-carboxamide derivatives and led us to discover the first single-digit nanomolar inhibitors of AC activity.[14] Importantly, selected compounds in this series sensitize certain types of cancer cells to the actions of cytotoxic agents, such as 5-fluorouracil and taxol, which is suggestive of a potential clinical use as chemosensitizers. Despite their considerable potency, the utility of these agents is hindered by low chemical and metabolic stability. Even the best compounds in this class have extremely short half-life times in mouse plasma (τ₁/₂ = 1–

---

** DOI: 10.1002/anie.201409042
3 min),[14] a limitation that extensive structure–stability studies have been as yet unable to overcome.[15] Thus, the field still needs suitable small molecules to foster probe and drug discovery efforts.

Here, we outline the discovery of the first class of potent AC inhibitors endowed with pronounced systemic activity. Elucidation of the mechanism through which these molecules inhibit AC along with in vivo pharmacokinetic and pharmacodynamic studies support the potential of this chemotype for the development of agents that target AC.

During the screening on human AC of a small library of compounds generated in our laboratory, we identified 2-oxo-N-(4-phenylbutyl)-1,3-benzoxazole-3-carboxamide (9a) as a nanomolar inhibitor of this enzyme (IC50 for human AC = 64 nM; Figure 3). Kinetic studies using human recombinant AC showed that 9a causes a concentration-dependent reduction in maximal catalytic velocity (Vmax) without affecting the Michaelis–Menten constant (Km; Figure 4).

This result, which is suggestive of a noncompetitive mechanism of action, was extended by liquid chromatography mass spectrometry (LC-MS) experiments, which showed that 9a covalently binds to the catalytic cysteine, Cys-143, of the enzyme.[16] Because 9a contains two electrophilic carbonyl groups, it may form distinct adducts with AC. As illustrated in Figure 5A, the nucleophilic attack of Cys-143 on the carbonyl group of urea would result in adducts A or B, whereas attack on the carbonyl group of the carbamate would result in adducts C or D. Incubation of purified recombinant human AC with 9a, followed by trypsin digestion and peptide analysis by LC-MS, showed the presence of a covalent adduct of 9a with the N-terminal peptide of AC (CTSI-VAEDK, Figure 5B, red trace). Control incubations of AC with DMSO showed only the native unmodified peptide (Figure 5B, black trace). Tandem MS analysis showed the formation of adduct A and indicated that the mass increase, corresponding to the carboxamide side chain of 9a, is carried by the N-terminal cysteine, confirming that this residue is the target of covalent binding (Figure 5C). We found no evidence supporting alternative hypotheses and no adducts of 9a with other AC tryptic peptides. These results indicate that 9a}

www.angewandte.org  © 2015 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

Angew. Chem. Int. Ed. 2015, 54, 485–489
inhibits human AC through S-acylation of catalytic Cys-143, with the benzoxazolone ring acting as the leaving group.

Encouraged by the potency and drug-likeness of 9a, which is based on the privileged scaffold of benzoxazolone,[17] we sought to expand this chemical class and identify structural features that are critical for AC inhibition. Focused structure–activity relationship (SAR) studies were first aimed at exploring the role of the urea moiety of 9a, with a small set of compounds (9b–e) that were prepared as described in Scheme 1.

Replacement of the carbonylic oxygen atom of the urea moiety of 9a with a sulfur atom gave compound 9b. This derivative showed limited chemical stability in [D6]DMSO, and was not studied further. The role of the 3-carboxamide NH group was then investigated by preparing the N-methyl derivative 9c and the corresponding carbamate 9d. The two compounds were efficiently accessed by activating the benzoxazolone 10 with triphosgene, followed by in situ treatment with the appropriate commercial amine 13 or alcohol 14, respectively. Both compounds 9c and 9d had no inhibitory activity on AC. Loss of activity was also observed when the urea moiety was replaced with an amide, as in compound 9e. These results demonstrate that the 3-carboxamide NH moiety is a key structural feature for AC inhibition (Table 1).

We expected that modulating the reactivity of these compounds would impact their stability. Therefore, we tested derivatives 9a, 16a, and 17a for their stability in buffers at acidic and neutral pH values, as well as in mouse plasma (Table 2). All compounds showed adequate stability under standard assay conditions (pH 4.5). When tested in phosphate-buffered saline (PBS, pH 7.4), the introduction of bromine in the para position to the urea moiety, as in compound 16a, led to a decrease of stability compared to 9a (16a, IC50 = 33 nM), while replacement of bromine with p-fluorophenyl had no significant effect (17a, IC50 = 79 nM; Table 1, entries 6–7).

The introduction of a bromine in the para position to the urea moiety, as in compound 16a, led to a two-fold increase in potency relative to 9a (16a, IC50 = 33 nM), while replacement of bromine with p-fluorophenyl had no significant effect (17a, IC50 = 79 nM; Table 1, entries 6–7). We expected that modulating the reactivity of these compounds would impact their stability. Therefore, we tested derivatives 9a, 16a, and 17a for their stability in buffers at acidic and neutral pH values, as well as in mouse plasma (Table 2). All compounds showed adequate stability under standard assay conditions (pH 4.5). When tested in phosphate-buffered saline (PBS, pH 7.4), the introduction of bromine in the para position to the urea moiety, as in compound 16a, led to a decrease of stability compared to 9a (16a, IC50 = 33 nM), while replacement of bromine with p-fluorophenyl group promoted stability (17a, IC50 = 79 nM; Table 1, entries 6–7).

Table 1: Inhibitory potencies (IC50) of compound 9a, analogues 9b–9e, and 16a–17a on human AC.

| Entry | Compound | R' | X | Y | IC50 [nM] ± S.E.M. |
|-------|----------|---|---|---|-------------------|
| 1     | 9a       | H | O | NH | 64 ± 7           |
| 2     | 9b       | H | S | NH | not stable       |
| 3     | 9c       | H | O | NCH3 | no inhibition |
| 4     | 9d       | H | O | O  | no inhibition    |
| 5     | 9e       | H | O | CH2 | no inhibition    |
| 6     | 16a      | Br| O | NH | 31 ± 9           |
| 7     | 17a      | p-F-Phe| O | NH | 79 ± 11          |

[a] IC50 values are expressed as means of at least three determinations.

Table 2: Stability of compounds 9a and 16a–17a by LC-MS analysis.

| Entry | Compound | Buffer stability | m-Plasma stability |
|-------|----------|------------------|--------------------|
| 1     | 9a       | 126 ± 3          | 45                 |
| 2     | 16a      | 294 ± 30         | 24                 |
| 3     | 17a      | > 360            | > 300              |

[a] NaCl (150 mM), NaH2PO4 (100 mM), trisodium citrate (100 mM), NP40 (1%), DTT (3 mM). [b] PBS. [c] Mouse plasma, 37°C.
compound 17a, stabilizes the benzoxazolone 3-carboxamide scaffold and, at the same time, appears to be well tolerated in terms of AC inhibitory potency. Stability experiments in mouse plasma showed that 17a has a substantially longer plasma half-life than does 9a (17a, t1/2 > 120 min) and is considerably more stable than the corresponding bromine derivative 16a (Table 2).

Furthermore, metabolic stability studies in mouse liver microsomes showed that 89% of 17a was recovered after an incubation time of one hour. Lastly, compound 17a was tested for off-target effects on a set of enzymes that includes proteases (aspartic, cysteine, and serine), lipoxygenases, cyclooxygenases, group IV phospholipase (sPLA2), and monoacylglycerol lipase. The compound showed no significant activity toward these targets, with the exception of a weak inhibitory effect on the aspartic protease cathepsin D (67% inhibition at 10 μM; Table S2, Supporting Information).

The favorable profile of 17a prompted us to test its ability to inhibit AC in intact cells. Human colon adenocarcinoma SW403 cells and mouse macrophage-like Raw 264.7 cells were incubated in the presence of 17a (0.1–20 μM). AC activity and sphingolipid levels were measured after various incubation times. The compound inhibited cellular AC activity with an IC50 of 825 nM in SW403 and 400 nM in Raw 264.7 cells (Figure 6A,B). Consistent with these results, incubation with 17a resulted in an increase in the levels of ceramide (d18:1/16:0) and a corresponding decrease in the levels of sphingosine. The levels of dihydroceramide (d18:0/16:0), which is cleaved by AC to sphinganine, were also increased (Figure 6C,D).

The effects of 17a persisted for 6 h, with a partial recovery of enzyme activity and consequent decrease in sphingolipid levels observed after 24 h (Figure 7). The results indicate that 17a inhibits AC in a complex cellular environment, leading to the intended biochemical response, that is, increased ceramide and decreased sphingosine levels.

Pharmacokinetic analyses showed that 17a quickly enters the bloodstream after a single intraperitoneal (i.p. 10 mg kg−1) and i.v. (1 mg kg−1) administration in mice (Figure 8A), reaching a maximal plasma concentration, Cmax, of 1767.9 ng mL−1 and displaying a half-life of 458 min in circulation. Relevant pharmacokinetic parameters are reported in Table S3 (Supporting Information). The primary in vivo metabolite of 17a, the hydrolysis product 19 (Figure 8B), did not inhibit AC in vitro at 10 μM.

Injection of 17a in mice (10 mg kg−1, i.p.) caused a substantial reduction in AC activity in multiple organs, including...
brain, liver, heart, lungs, and kidney (Figure 8C). Highest levels of baseline AC activity and AC inhibition were found in lung tissue, which was selected for further analyses. As expected, we observed a significant increase in ceramide species that are preferred substrates for AC (namely, d18:1/14:0, d18:1/16:0, and d18:1/18:0) along with a concomitant decrease in sphingosine (Figure 8D). The levels of ceramides with longer fatty acyl chains, which are not preferred substrates for AC, were not affected (Table S4, Supporting Information). Compound 17a appeared to be well tolerated at the dosage tested. These findings show that 17a inhibits AC in live animals, resulting in the predicted alteration of the balance between ceramide and sphingosine.

In conclusion, we identified the first class of potent and systemically active inhibitors of intracellular AC activity. These compounds act as covalent inhibitors of AC. Focused SAR studies showed that an unsubstituted nitrogen atom in the 3-carboxamide moiety is mandatory for activity, and highlighted that the introduction of a p-fluorophenyl group on the benzoxazolone ring balanced potency and stability (both chemical and metabolic), as shown with compound 17a. Notably, these features are coupled with the ability of 17a to inhibit AC in various cell lines as well as in vivo. Thus, our results identify compound 17a as the first potent chemical probe that may be used to investigate the physiopathological roles of ceramide and as starting point for the discovery of novel therapeutic agents. Further expansion of this chemical class will be reported in due course.

Received: September 12, 2014
Published online: November 13, 2014

Keywords: acid ceramidase · cancer · ceramide · enzyme inhibition · sphingosine-1-phosphate

[1] a) Y. A. Hannun, L. M. Obeid, Nat. Rev. Mol. Cell Biol. 2008, 9, 139–150; b) N. Bartke, Y. A. Hannun, J. Lipid Res. 2009, 50, 591–96.
[2] a) B. Ogretmen, Y. A. Hannun, Nat. Rev. Cancer 2004, 4, 604–616; b) P. Gangoiti, L. Camacho, L. Arana, A. Ouro, M. H. Granado, L. Brizuela, J. Casas, G. Fabrias, J. L. Abad, A. Delgado, A. Gomez-Munoz, Prog. Lipid Res. 2010, 49, 316–334; c) M. T. Dimanche-Boitrel, A. Rebillard, Handb. Exp. Pharmacol. 2013, 216, 73–91.
[3] a) D. Salvemini, T. Doyle, M. Kress, G. Nicol, Trends Pharmacol. Sci. 2013, 34, 110–118; b) G. J. Patti, O. Yanes, L. P. Shriver, J. P. Courade, R. Tautenhahn, M. Manchester, G. Siuzdak, Nat. Chem. Biol. 2012, 8, 232–234.
[4] C. Mao, L. M. Obeid, Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2008, 1781, 424–434.
[5] X. Huang, B. R. Withers, B. C. Dickson, Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2014, 1841, 657–664.
[6] M. Maceyka, S. Spiegel, Nature 2014, 510, 58–67.
[7] a) B. J. Pettus, C. E. Chalfant, Y. A. Hannun, Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2002, 1585, 114–125; b) A. Morales, H. Lee, F. M. Goni, R. Kolesnick, J. C. Fernandez-Checa, Apoptosis 2007, 12, 923–939; c) W. C. Huang, C. L. Chen, Y. S. Lin, C. F. Lin, J. Lipids 2011, 565316.
[8] a) S. Spiegel, M. Mästlin, Nat. Rev. Mol. Cell Biol. 2003, 4, 397–407; b) K. Takabe, S. Spiegel, J. Lipid Res. 2014, 55, 1839–1846.
[9] a) P. Nussbaumer, ChemMedChem 2008, 3, 543–551; b) D. Canals, D. M. Perry, R. W. Jenkins, Y. A. Hannun, Br. J. Pharmacol. 2011, 163, 694–712; c) A. Adan-Gokbulut, M. Kartal-Yandim, G. Iskender, Y. Baran, Curr. Med. Chem. 2013, 20, 108–122; d) J. Truman, M. Garcia-Barras, L. M. Obeid, Y. A. Hannun, Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2014, 1841, 1174–1188.
[10] a) C. R. Gault, L. M. Obeid, Y. A. Hannun, Adv. Exp. Med. Biol. 2010, 688, 1–23.
[11] E. M. Saied, C. Arenz, Cell Physiol. Biochem. 2014, 34, 197–212.
[12] a) A. Bielawska, M. S. Greenberg, D. Perry, S. Jayadev, J. A. Shayman, C. McKay, Y. A. Hannun, J. Biol. Chem. 1996, 271, 12646–12654; b) M. Raisova, G. Goltz, M. Bektas, A. Bielaw ska, C. Riebeling, C. McKay, Y. A. Hannun, C. E. Orfáanos, C. C. Geilen, FEBS Lett. 2002, 516, 47–52; c) C. Bedia, D. Canals, X. Matacobs, Y. Harrak, J. Casas, A. Llebaria, A. Delgado, G. Fabrias, Chem. Phys. Lipids 2008, 156, 33–40; d) A. Bai, Z. M. Szulc, J. Bielawski, N. Mayroo, X. Liu, J. Norris, Y. A. Hannun, A. Bielawska, Bioorg. Med. Chem. 2009, 17, 1840–1848; e) D. Proksch, J. K. Klein, C. Arenz, J. Lipids 2011, 971618; f) J. M. Draper, Z. Xia, R. A. Smith, Y. Zhuang, W. Wang, C. D. Smith, Mol. Cancer Ther. 2011, 10, 2052–2061.
[13] See the Supporting Information (Table S1) for a summary of AC inhibitory activity data for compounds 1–7 and assay methods.
[14] N. Realini, C. Solorzano, C. Pagliuca, D. Pizzirani, A. Armirioti, R. Luciani, M. P. Costi, T. Bandiera, D. Piomelli, Sci. Rep. 2013, 3, 1035.
[15] D. Pizzirani, C. Pagliuca, N. Realini, D. Branduardi, G. Bottegoni, M. Mor, F. Bertozzi, R. Scarpelli, D. Piomelli, T. Bandiera, J. Med. Chem. 2013, 56, 3518–3530.
[16] N. Shiraiantz, E. Elyahu, J. H. Park, X. He, R. Shalgi, E. H. Schuchman, J. Biol. Chem. 2008, 283, 11253–11259.
[17] J. Poupaert, P. Carato, E. Colacino, S. Yous, Curr. Med. Chem. 2005, 12, 877–885.